Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
- Peter Gasser, Dominique H Holstein, R. Brenneisen
- Psychology, MedicineJournal of Nervous and Mental Disease
- 30 June 2014
Results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.
The Pharmacology of Lysergic Acid Diethylamide: A Review
- T. Passie, J. Halpern, D. Stichtenoth, H. Emrich, A. Hintzen
- Psychology, MedicineCNS Neuroscience & Therapeutics
- 1 December 2008
There is new interest in LSD as an experimental tool for elucidating neural mechanisms of (states of) consciousness and there are recently discovered treatment options with LSD in cluster headache and with the terminally ill.
The pharmacology of psilocybin
All the available pharmacological data about psilocybin are presented and its still growing capacity for abuse and the widely dispersed data are presented.
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
- Peter Gasser, Katharina Kirchner, T. Passie
- Psychology, MedicineJournal of Psychopharmacology
- 1 January 2015
Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms in patients with life-threatening diseases.
Reviewing the Potential of Psychedelics for the Treatment of PTSD
- E. Krediet, T. Bostoen, J. Breeksema, A. V. van Schagen, T. Passie, E. Vermetten
- PsychologyInternational Journal of Neuropsychopharmacology
- 14 March 2020
This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids, and describes the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD.
Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
- J. Halpern, A. Sherwood, T. Passie, K. C. Blackwell, A. J. Ruttenber
- MedicineMedical Science Monitor
- 1 August 2008
For those who have religious need for ingesting ayahuasca, from a psychiatric and medical perspective, these pilot results substantiate some claims of benefit, especially if subjects interviewed fully reflect general membership.
Genuine and drug-induced synesthesia: A comparison
Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
- T. Passie, H. Emrich, M. Karst, S. Brandt, J. Halpern
- Psychology, BiologyDrug Testing and Analysis
- 1 July 2012
It is shown that recent studies provided supporting evidence that PTSD patients may be able to cope with their symptoms by using cannabis products and it is concluded that further studies are warranted in order to evaluate the therapeutic potential of cannabinoids in PTSD.
A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD.
Results of the survey suggest that HPPD is in most cases due to a subtle over-activation of predominantly neural visual pathways that worsens anxiety after ingestion of arousal-altering drugs, including non-hallucinogenic substances.
The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
This study investigates the efficacy of a nonhallucinogenic analog of LSD, BOL-148, which has been studied in volunteers and in patients suffering from vascular headaches but not, apparently, in patients with CH.